Recruiting

JOCOAT(TM) APN-3003

Sponsor:

ARC Medical Inc.

Code:

NCT07081815

Conditions

Surgical Adhesions

Eligibility Criteria

Sex: All

Age: 15 - 25

Healthy Volunteers: Not accepted

Interventions

JOCOAT(TM) APN-3003

Study Details

Brief summary:

This study will assess the safety and efficacy of a new liquid anti-adhesion device, JOCOAT(TM) APN-3003 in patients undergoing knee anterior cruciate ligament reconstruction (ACLR) surgery.

This is a single-center, prospective study. Safety and clinical outcomes will be compared with historical controls from enrolled study site patients from NCT03935750 (STABILITY 2) which has evaluated outcomes following ACL rupture in young athletes.

A maximum of 24 patients aged 15-25 years undergoing primary anatomic ACLR with quadriceps tendon (QT) graft following a standardized surgical treatment algorithm will be enrolled. All patients will receive JOCOAT(TM) APN-3003 at the end of their surgery.

Conditions

Surgical Adhesions

Study ID

NCT07081815

Start date

Sep 5, 2025

Status verified date

Nov, 2026

Completion date

Nov, 2027

Anticipated

Primary completion date

Nov, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 15 - 25

Healthy Volunteers: Not accepted

Pre-operative Inclusion Criteria:

  • Understand and be able to follow the requirements of the protocol including personally signing and dating an REB approved Informed Consent Form prior to undergoing any protocol related procedures
  • Subjects aged 15 to 25 years with an ACL-deficient knee undergoing primary ACLR
  • Subjects with skeletal maturity (i.e. closed epiphyseal growth plates on standard knee radiographs)
  • At least two of the following factors that are associated with a high risk of graft failure:

1. participate in a competitive pivoting sport (defined as sports that include cutting and pivoting activities such as basketball, American football, soccer, lacrosse, volleyball, tennis/squash, handball, downhill skiing etc);
2. have a pivot shift of grade 2 or greater;
3. have generalized ligamentous laxity (Beighton score of >= 4) and/or genu recurvatum > 10 degrees
  • Biological females have a negative pregnancy test within 4 days of initial surgery
  • Is willing, able and likely to fully comply with clinical trial procedures and restrictions including follow-ups

Pre-operative Exclusion Criteria:

  • Simultaneous bilateral ACLR
  • Previous ACLR on either knee
  • Less than one year from contralateral knee or contralateral/ipsilateral hip/ankle surgery
  • Prior arthrotomy in the study knee
  • Active infection anywhere or previous infection in the study knee
  • History of peri-articular fracture in study knee
  • > 3 degrees of asymmetric varus or valgus
  • The patient has debilitating knee pain that would preclude the use of QT tissue as a graft
  • The patient has a significant quad tendonitis that would preclude the use of QT tissue as a graft
  • Known or suspected allergy to brown seaweed, seaweed-based materials such as fucoidan, food allergies and/or presence of any allergy related dietary restrictions unless deemed by the investigator as "Not Clinically Significant"
  • Known or suspected allergy to fucose, galactose, sulfur, sulfate, sulfite, or any sugar-based polymer or polysaccharides containing these
  • Known hypersensitivity to sodium lactate or sulfur-containing compounds
  • Any other severe allergic conditions or previous reactions (e.g., anaphylactic reactions, angioedema)
  • Severe metabolic acidosis or alkalosis
  • Have insulin dependent diabetes, severe diabetes and/or poorly controlled diabetes mellitus
  • Any general medical or surgical condition that would preclude a standard knee ACLR
  • Inflammatory arthropathy
  • Breast feeding
  • Have a medical condition that, in the opinion of the investigator would interfere with the evaluation of the safety or efficacy of the investigational product
  • Have received any investigational products that, in the opinion of the investigator, would interfere with the evaluation of the safety or efficacy of the investigational product
  • Have clinically relevant hemochromatosis, hepatic, renal, autoimmune, lymphatic, hematological or coagulation disorders
  • Family history of blood or coagulation disorders
  • History of heparin-induced thrombocytopenia (HIT) or known sensitivity to heparin-like products

Intra-operative Inclusion Criteria:

\- Patient undergoes primary anatomic anterior cruciate ligament reconstruction surgery with quadriceps tendon (QT) graft

Intra-operative Exclusion Criteria:

  • Pre-existing arthrofibrosis in the knee
  • Partial ACL rupture (defined as one bundle ACL tear requiring reconstruction/ augmentation of the torn bundle with no surgery required for the intact bundle) where ACLR is not performed
  • Multiple ligament injury (two or more ligaments requiring surgery)
  • Symptomatic articular cartilage defect requiring treatment other than debridement
  • Articular cartilage lesion that requires any other surgical treatment apart from debridement
  • Under anesthetic, this patient has a symmetrical or grade 1 pivot shift AND has a Beighton score <4 AND <10 degrees hyperextension

Study Design

Enrollment

24 participants

Anticipated

Intervention Model

Single group

Primary purpose

Prevention

Interventions and Outcome Measures

Arms

experimental: JOCOAT(TM) APN-3003

Intra-articular injection

Interventions

JOCOAT(TM) APN-3003

10 mL of JOCOAT(TM) APN-3003 is applied at the end of surgery

Primary outcome measure

  • Safety of JOCOAT(TM) APN-3003 as measured by number and severity of adverse device effects and serious adverse device effects [ Time Frame: 3 months after surgery ]

Central Contacts and Locations

Locations

Western University

Recruiting

London, Ontario, Canada

Contacts

More Information

Sponsor

ARC Medical Inc.

Last update posted

Nov 18, 2026

Last verified

Nov, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-19. This information was provided to ClinicalTrials.gov by ARC Medical Inc. on 2026-11-18. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.